Question: The reference cited below notes “Over the past decade, artemisinin-based combination therapies (ACTs) have been deployed as first- and second- line treatments for uncomplicated malaria across malaria-endemic regions. Since 2001, this deployment has included the delivery of over 500 million treatments of artemether-lumefantrine (AL), making it one of the most widely prescribed drugs worldwide”. What neurologic toxicity is of most concern in patients receiving ACTs?
Answer: Neuroauditory toxicity is the neurologic toxicity of most concern in patients receiving ACTs. (Ramos-martin V et al. Review Article: Neuroauditory toxicity of artemisinin combination therapies—Have safety concerns been addressed? 2014 Am J Trop Hyg 91(1):62-73)